| Dr Michael Leroy Reynolds, MD | |
|
912 Third Street, Suite 101, Greensboro, NC 27405-6967 | |
| (336) 273-2511 | |
| (336) 370-0287 |
| Full Name | Dr Michael Leroy Reynolds |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 28 Years |
| Location | 912 Third Street, Greensboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073579066 | NPI | - | NPPES |
| 130023851 | Other | NC | PALMETTO GBA RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 2001-00453 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Duke Regional Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.
Ovarian cancer, one of the deadliest malignancies, is actually a constellation of different cancers that may originate in other organs and should not be treated as a single disease, concludes a new congressionally mandated report on the state of ovarian cancer incidence, treatment and research. The report, published by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine, also highlights persistent serious disparities in delivery of care across different groups of women in the U.S., and suggests promising areas for further research.
Small employers are traditionally faced with a difficult choice when providing health coverage for their employees: they can either choose benefits that are affordable, or spend more and offer their employees a choice.
› Verified 8 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.
Ovarian cancer, one of the deadliest malignancies, is actually a constellation of different cancers that may originate in other organs and should not be treated as a single disease, concludes a new congressionally mandated report on the state of ovarian cancer incidence, treatment and research. The report, published by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine, also highlights persistent serious disparities in delivery of care across different groups of women in the U.S., and suggests promising areas for further research.
Small employers are traditionally faced with a difficult choice when providing health coverage for their employees: they can either choose benefits that are affordable, or spend more and offer their employees a choice.
› Verified 8 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.
Ovarian cancer, one of the deadliest malignancies, is actually a constellation of different cancers that may originate in other organs and should not be treated as a single disease, concludes a new congressionally mandated report on the state of ovarian cancer incidence, treatment and research. The report, published by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine, also highlights persistent serious disparities in delivery of care across different groups of women in the U.S., and suggests promising areas for further research.
Small employers are traditionally faced with a difficult choice when providing health coverage for their employees: they can either choose benefits that are affordable, or spend more and offer their employees a choice.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Leroy Reynolds, MD Po Box 29568, Greensboro, NC 27429-9568 Ph: (336) 273-2511 | Dr Michael Leroy Reynolds, MD 912 Third Street, Suite 101, Greensboro, NC 27405-6967 Ph: (336) 273-2511 |
News Archive
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.
Ovarian cancer, one of the deadliest malignancies, is actually a constellation of different cancers that may originate in other organs and should not be treated as a single disease, concludes a new congressionally mandated report on the state of ovarian cancer incidence, treatment and research. The report, published by the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine, also highlights persistent serious disparities in delivery of care across different groups of women in the U.S., and suggests promising areas for further research.
Small employers are traditionally faced with a difficult choice when providing health coverage for their employees: they can either choose benefits that are affordable, or spend more and offer their employees a choice.
› Verified 8 days ago
Dr. Kim Gloria Hoover, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 510 N Elam Ave Ste 301, Greensboro, NC 27403 Phone: 336-832-9800 Fax: 336-832-1369 | |
Dr. Gerald Dale Taylor, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 201 N Eugene St, Greensboro, NC 27401 Phone: 336-641-3630 | |
Eliot Julian Lewit, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2721 Horse Pen Creek Rd, Ste 104, Greensboro, NC 27410 Phone: 336-268-2530 Fax: 336-268-2531 | |
Janardhana Rao Jonnalagadda, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 2016 New Garden Rd, Suite C, Greensboro, NC 27410 Phone: 336-541-8111 Fax: 855-427-6593 | |
Dr. Keertan Reddy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 603 Dolley Madison Rd Ste 100, Greensboro, NC 27410 Phone: 216-545-8229 Fax: 217-545-2275 | |
Dr. Kumbaiah N Murthy, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 201 N Eugene St, Greensboro, NC 27401 Phone: 336-676-6840 Fax: 336-676-6490 |